Kim Blenman, PhD, MS

Assistant Professor of Medicine (Medical Oncology) and Assistant Professor of Computer Science

DownloadHi-Res Photo

Appointments

Medical Oncology and Hematology

Primary

About

Titles

Assistant Professor of Medicine (Medical Oncology) and Assistant Professor of Computer Science

Biography

Dr Blenman is an immunologist, clinical chemist, and computer scientist with expertise in clinical and translational research. She uses and develops novel software tools and wet lab methods to understand the mechanisms responsible for disparities in disease pathogenesis, therapeutic response, and therapy-induced toxicity.

Last Updated on July 31, 2024.

Appointments

Medical Oncology and Hematology
Assistant Professor
Primary

Center for Breast Cancer
Genomics, Genetics, and Epigenetics
Internal Medicine
Janeway Society
Medical Oncology and Hematology
MORE
Status of Women in Medicine Committee (SWIM)
Yale Cancer Center

Education & Training

Postdoctoral Fellow: City of Hope Comprehensive Cancer Center

Fellowship: University of California – College of Medicine, San Francisco

PhD: University of Florida College of Medicine

MS: University of Florida College of Medicine

Research

Overview

Medical Research Interests

Algorithms; Breast Neoplasms; Clinical Trial; Computer Graphics; Data Visualization; Head and Neck Neoplasms; Image Processing, Computer-Assisted; Immunotherapy; Medical Informatics Computing; Melanoma; Multiomics; Multiple Myeloma

Public Health Interests

Bioinformatics; Biomarkers; Cancer; Clinical Trials; Immunology; Pharmaceuticals and Medical Devices

ORCID
0000-0001-6070-0728
Blenman Innovation Group
View Lab Website

Publications

2026

Blood‐based proteomic profiling reveals context‐dependent changes in BCL2‐associated signaling during taxane therapy in breast cancer patients
Munshani S, Ibrahim E, Rodwin R, Ferrucci L, Blenman K, Lustberg M, Ehrlich B. Blood‐based proteomic profiling reveals context‐dependent changes in BCL2‐associated signaling during taxane therapy in breast cancer patients. FEBS Open Bio 2026 PMID: 41883148, DOI: 10.1002/2211-5463.70239.
Peer-Reviewed Original Research
Clarifying validation terminologies in healthcare
Dy A, Buetow S, Bredemeyer A, Saini M, Lucas F, Bennett S, Blenman K, Wharton K, Singhal S, de Baca M, Schap K, Hanna M, Kearney S, Zerbe N, Salgado R, Veetil J, Seheult J, McClintock D, Khademi A, Lennerz J. Clarifying validation terminologies in healthcare. Npj Digital Medicine 2026, 9: 318. PMID: 41787064, PMCID: PMC13079824, DOI: 10.1038/s41746-026-02471-2.
Peer-Reviewed Original Research

2025

Adverse events in patients treated with neoadjuvant chemo/immunotherapy for triple negative breast cancer: results from seven academic medical centers
Mezzanotte-Sharpe J, Hsu C, Choi D, Sheffield H, Zelinskas S, Proskuriakova E, Montalvo M, Lee D, Whisenant J, Gaffney K, Thompson M, Blenman K, Tawagi K, Symonds L, Santa-Maria C, Unni N, Quiroga D, Shyr Y, Kennedy L. Adverse events in patients treated with neoadjuvant chemo/immunotherapy for triple negative breast cancer: results from seven academic medical centers. Breast Cancer Research And Treatment 2025, 213: 71-80. PMID: 40613977, PMCID: PMC12259778, DOI: 10.1007/s10549-025-07758-8.
Peer-Reviewed Original Research
MeSH Keywords
Dynamic clustering of genomics cohorts beyond race, ethnicity—and ancestry
Mohsen H, Blenman K, Emani P, Morris Q, Carrot-Zhang J, Pusztai L. Dynamic clustering of genomics cohorts beyond race, ethnicity—and ancestry. BMC Medical Genomics 2025, 18: 87. PMID: 40375077, PMCID: PMC12082885, DOI: 10.1186/s12920-025-02154-z.
Peer-Reviewed Original Research
MeSH Keywords
A comprehensive evaluation of diversity measures for TCR repertoire profiling
Mika J, Polanska A, Blenman K, Pusztai L, Polanska J, Candéias S, Marczyk M. A comprehensive evaluation of diversity measures for TCR repertoire profiling. BMC Biology 2025, 23: 133. PMID: 40369611, PMCID: PMC12080070, DOI: 10.1186/s12915-025-02236-5.
Peer-Reviewed Original Research
MeSH Keywords
Accelerated Aging in Cancer and Cancer Treatment: Current Status of Biomarkers
Abraham S, Parekh J, Lee S, Afrin H, Rozenblit M, Blenman K, Perry R, Ferrucci L, Liu J, Irwin M, Lustberg M. Accelerated Aging in Cancer and Cancer Treatment: Current Status of Biomarkers. Cancer Medicine 2025, 14: e70929. PMID: 40322791, PMCID: PMC12051034, DOI: 10.1002/cam4.70929.
Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus Statements
MeSH Keywords
Immune-related adverse events are associated with better event-free survival in a phase I/II clinical trial of durvalumab concomitant with neoadjuvant chemotherapy in early-stage triple-negative breast cancer
Rios-Hoyo A, Dai J, Noel T, Blenman K, Park T, Pusztai L. Immune-related adverse events are associated with better event-free survival in a phase I/II clinical trial of durvalumab concomitant with neoadjuvant chemotherapy in early-stage triple-negative breast cancer. ESMO Open 2025, 10: 104494. PMID: 40107153, PMCID: PMC11964624, DOI: 10.1016/j.esmoop.2025.104494.
Peer-Reviewed Original Research
MeSH Keywords

2024

Circulating tumor DNA fraction predicts residual cancer burden post-neoadjuvant chemotherapy in triple negative breast cancer
Shan N, Gould B, Wang X, Bonora G, Blenman K, Foldi J, Campos G, Walsh M, Du P, Pusztai L. Circulating tumor DNA fraction predicts residual cancer burden post-neoadjuvant chemotherapy in triple negative breast cancer. The Journal Of Liquid Biopsy 2024, 6: 100168. PMID: 40027305, PMCID: PMC11863946, DOI: 10.1016/j.jlb.2024.100168.
Peer-Reviewed Original Research
Microbiome-Based Cancer Therapeutics
Luvhengo T, Miya T, Demetriou D, Blenman K, Dlamini Z. Microbiome-Based Cancer Therapeutics. 2024, 208-226. DOI: 10.1201/9781032706450-16.
Chapters
Peripheral blood immune parameters, response, and adverse events after neoadjuvant chemotherapy plus durvalumab in early-stage triple-negative breast cancer
Foldi J, Blenman K, Marczyk M, Gunasekharan V, Polanska A, Gee R, Davis M, Kahn A, Silber A, Pusztai L. Peripheral blood immune parameters, response, and adverse events after neoadjuvant chemotherapy plus durvalumab in early-stage triple-negative breast cancer. Breast Cancer Research And Treatment 2024, 208: 369-377. PMID: 39002068, DOI: 10.1007/s10549-024-07426-3.
Peer-Reviewed Original Research

See All Publications

Academic Achievements & Community Involvement

See Below

Honors

honor
Career Development Award
03/31/2022National AwardBreast Cancer Research Foundation-American Association for Cancer Research (BCRF-AACR)
Details
honor
Blavatnik Funding and Pitchfest 2019 Quarterfinalist
09/03/2018Yale University AwardYale University
Details
honor
Melanoma Research Alliance Young Investigator Award
05/15/2015National AwardMelanoma Research Alliance
Details

News & Links

Media

Kim R.M. Blenman* and Marcus W. Bosenberg. Immune cell and cell cluster phenotyping, quantitation, and visualization using in silico multiplexed images and tissue cytometry. Cytometry A, 2019. PMID: 30468565. [*Corresponding Author].

News

See All News

Related Links

Get In Touch

Administrative Support

Michele Orosz
Senior Administrative Assistant

Appointments

Titles

Biography

Appointments

Medical Oncology and Hematology

Other Departments & Organizations

Education & Training

Overview

Medical Research Interests

Public Health Interests

ORCID

Blenman Innovation Group

Publications

2026

2025

2024

Honors

Career Development Award

Blavatnik Funding and Pitchfest 2019 Quarterfinalist

Melanoma Research Alliance Young Investigator Award

Media

Dr Blenman's Computational Histology Approach Featured on the Cover of Cytometry April 2019 Volume 95A Issue 4

News

Yale Cancer Center presents advances in breast cancer at the San Antonio Breast Cancer Symposium

Yale Cancer Center Faculty and Trainees Present at AACR Annual Meeting

Yale Cancer Center Researchers Awarded 2023-2024 Grants from the Breast Cancer Research Foundation

Smilow Shares CME: Perspectives on the USPSTF Breast Screening Recommendations

Related Links

Administrative Support